{"commentary":{"count":50,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":26,"podcast":16,"x_thread":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05774951\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CAMBRIA-1","nct_id":"NCT05774951","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cambria-1-nct05774951. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CAMBRIA-1","arms":[{"description":"Continue standard endocrine therapy of investigator's choice (aromatase inhibitors \\[AI; exemestane, letrozole, anastrozole\\] or tamoxifen)","label":"Arm A: standard endocrine therapy of investigator´s choice","type":"ACTIVE_COMPARATOR"},{"description":"Camizestrant","label":"Arm B: camizestrant","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2036-05-29","type":"ESTIMATED"},"conditions":["Breast Cancer, Early Breast Cancer"],"enrollment":{"count":4300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Camizestrant","type":"DRUG"},{"name":"Tamoxifen","type":"DRUG"},{"name":"Anastrozole","type":"DRUG"},{"name":"Letrozole","type":"DRUG"},{"name":"Exemestane","type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"AstraZeneca","official_title":"CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-04-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive breast cancer-free survival (IBCFS)","timeFrame":"Up to 10 years"}],"references":[{"citation":"Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. Future Oncol. 2025 Mar;21(7):795-806. doi: 10.1080/14796694.2025.2459548. Epub 2025 Feb 27.","pmid":"40017004","type":"DERIVED"}],"start_date":{"date":"2023-03-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","url":"https://clinicaltrials.gov/study/NCT05774951"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cambria-1-nct05774951"}